Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Hativ® elektrokardiogrammonitorering på patienter med mistanke om arytmi (HELP-A)

1. september 2026 opdateret af: Young Jun Park, Wonju Severance Christian Hospital
HELP-A studie er et enkeltcenter, randomiseret, kontrolleret forsøg. I alt 588 patienter indrulleredes i løbet af de 2 års indskrivningsperiode og fulgtes i 1 måneds opfølgningsperiode. Denne undersøgelse har til formål at sammenligne diagnostisk udbytte mellem kontinuerlig EKG-plaster og intermitterende håndholdt EKG hos patienter med arytmisymptomer.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

HELP-A-studie er et enkeltcenter, randomiseret, kontrolleret forsøg designet til at sammenligne diagnostisk udbytte, arytmidetektion, brugervenlighed og omkostningseffektivitet mellem kontinuerlig EKG-plaster og intermitterende håndholdt EKG hos patienter med arytmisymptomer. Patienter, der har symptomer på arytmi, men som ikke er diagnosticeret på et 12-aflednings-EKG og kræver yderligere tests. I alt 588 patienter indrulleredes i løbet af de 2 års indskrivningsperiode og fulgtes i 3 måneders opfølgningsperiode. Patienterne vil blive tildelt kontinuerligt plaster-EKG eller intermitterende håndholdt EKG og vil blive undersøgt i en måned. Hvis der ikke er nogen diagnose efter en måned, vil patienten blive overført til en anden enhed og undersøgt i endnu en måned.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

588

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

  • Sydkorea
    • Dong-gu Jaebongro 42
      • Gwangju, Dong-gu Jaebongro 42, Sydkorea, 61469
        • Rekruttering
        • Chonnam National University Hospital
        • Kontakt:
    • Gangwon-do
      • Wŏnju, Gangwon-do, Sydkorea, 26426
    • Hwaseong-si Keunjaebong-gil 7
      • Gyeonggi-do, Hwaseong-si Keunjaebong-gil 7, Sydkorea, 18450
        • Rekruttering
        • Hallym University Dongtan Sacred Heart Hospital
        • Kontakt:
    • Seongbuk-gu, 73 Goryeodae-ro
      • Seoul, Seongbuk-gu, 73 Goryeodae-ro, Sydkorea, 02841
        • Rekruttering
        • Korea University Anam Hospital
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inklusionskriterier:

  • Patienter, der har arytmisymptomer, men som ikke er diagnosticeret på et 12-aflednings elektrokardiogram og kræver yderligere tests.
  • Patienter, der kan bruge en smartphone

Ekskluderingskriterier:

  • Patienter, der har hjerteimplanterbare elektroniske enheder (CIED'er)
  • Patienter, der ikke kan bruge håndholdt EKG

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Diagnostisk
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Memo Patch continuous ECG strategy
Participants undergo continuous single-lead ECG monitoring with Memo Patch for up to 7 consecutive days and report symptom onset using a mobile messaging chatbot or paper diary.
Enhed: Memo Patch continuous ECG
Continuous single-lead ECG monitoring for up to 7 consecutive days. Participants report the onset of symptoms using a mobile messaging chatbot or paper diary. For each reported symptomatic episode, a 20-minute ECG segment extending from 10 minutes before to 10 minutes after the reported onset is available for review.
Aktiv komparator: Hativ handheld ECG strategy
Participants use Hativ for 30 days and perform 10-second 6-lead ECG recordings at least twice daily and whenever symptoms occur.
Enhed: Hativ handheld ECG
Handheld ECG monitoring using 10-second 6-lead recordings obtained at least twice daily and additionally whenever symptoms occur for 30 days. Recordings are transmitted through the companion smartphone application to a secure study server.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Clinically informative symptom-rhythm correlation with the initially assigned device by 1 month
Tidsramme: From randomization through the 1-month follow-up visit
Proportion of randomized participants with at least one participant-confirmed typical symptomatic episode documented with an interpretable ECG using the initially assigned device by the 1-month follow-up visit and before optional sequential monitoring. Primary-endpoint success comprises either a positive symptom-rhythm correlation or a negative-only symptom-rhythm correlation. A positive correlation is a qualifying symptomatic episode with an interpretable ECG showing a rhythm finding judged by central adjudication to be temporally and clinically concordant with that episode. A negative-only correlation requires at least one qualifying symptomatic episode with an interpretable ECG showing no concordant rhythm finding and no positive correlation by the 1-month visit.
From randomization through the 1-month follow-up visit

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Positive symptom-rhythm correlation
Tidsramme: By the 1-month follow-up visit
Proportion of participants with at least one qualifying participant-confirmed typical symptomatic episode documented with an interpretable ECG showing a rhythm finding judged by central adjudication to be temporally and clinically concordant with that episode.
By the 1-month follow-up visit
Negative-only symptom-rhythm correlation
Tidsramme: By the 1-month follow-up visit
Proportion of participants with at least one qualifying participant-confirmed typical symptomatic episode documented with an interpretable ECG showing no temporally and clinically concordant rhythm finding and with no positive correlation by the 1-month follow-up visit.
By the 1-month follow-up visit
Both positive and negative episodes
Tidsramme: By the 1-month follow-up visit
Proportion of participants with at least one qualifying positive symptom-rhythm correlation and at least one qualifying negative symptom-rhythm correlation. This measure is descriptive.
By the 1-month follow-up visit
Clinically significant arrhythmia detected during assigned-device monitoring
Tidsramme: By the 1-month follow-up visit
Proportion of participants with at least one centrally adjudicated clinically significant arrhythmia detected during initially assigned-device monitoring, irrespective of symptom association. Clinically significant arrhythmias are classified using prespecified device-specific operational definitions. Findings are additionally classified as symptom-associated or not temporally associated with a qualifying typical symptomatic episode.
By the 1-month follow-up visit
Arrhythmia-directed therapeutic intervention
Tidsramme: Through 3 months after randomization
Rate and timing of arrhythmia-directed therapeutic interventions, including medication, catheter ablation, or cardiac device implantation.
Through 3 months after randomization
Overall satisfaction
Tidsramme: 1-month follow-up visit
Overall device satisfaction measured using the prespecified ordinal response scale in the 1-month participant questionnaire.
1-month follow-up visit
EQ-5D-5L
Tidsramme: Baseline to 1 month
Change in the EQ-5D-5L index score from enrollment to the 1-month follow-up visit.
Baseline to 1 month
Healthcare resource utilization and costs
Tidsramme: Through 3 months after randomization
Arrhythmia-related healthcare resource use through 3 months, including additional diagnostic tests, arrhythmia-related medications, emergency department visits, and hospitalizations. Costs are derived from institutional billing records at participating centers and expressed in Korean won. The base-case analysis excludes acquisition cost of the study devices because the devices were supplied in kind.
Through 3 months after randomization
Safety Outcome
Tidsramme: Through 3 months after randomization
Number and proportion of participants experiencing device-related or serious adverse events. Expected device-related events include skin irritation or contact dermatitis associated with the adhesive patch and discomfort associated with device use.
Through 3 months after randomization

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Sequential-monitoring participant questionnaire
Tidsramme: 3-month follow-up
Among participants who undergo optional sequential monitoring with both study devices, paired ratings of device usability, overall satisfaction, preference, willingness to recommend, and willingness to use each device again are collected using the 3-month head-to-head questionnaire. This analysis is exploratory because eligibility for sequential monitoring depends on the outcome of the initially assigned strategy
3-month follow-up

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Wonju Severance Christian Hospital

Efterforskere

  • Ledende efterforsker: Young Jun Park, MD, Wonju Severance Christian Hopsital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. februar 2024

Primær færdiggørelse (Anslået)

31. december 2026

Studieafslutning (Anslået)

31. december 2026

Datoer for studieregistrering

Først indsendt

31. januar 2024

Først indsendt, der opfyldte QC-kriterier

7. februar 2024

Først opslået (Faktiske)

9. februar 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • CR223024

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data underlying the primary publication, together with a data dictionary, will be available from the corresponding investigator on reasonable request after completion of the study and publication of the primary results, subject to ethics approval and execution of an appropriate data-use agreement.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner